GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AKBA · Mar 31, 2026

Akebia Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001517022-26-000039General Corporate
Debt relative to revenue70thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.debt_to_revenue

91.31% · OPTIONAL · VALID

Capex intensity63thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.12% · OPTIONAL · VALID

Operating cash generation10thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-39.61% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-6.61% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

24.27% · OPTIONAL · VALID

Gross margin60thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.gross_margin

77.05% · CORE · VALID

Operating margin60thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

-8.77% · CORE · VALID

R&D intensity70thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

27.65% · OPTIONAL · VALID

SBC intensity90thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.85% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesHistory building
Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
20.43%
Current
91.31%
Delta
70.88%
Capex Intensity Decreased
Previous
0.12%
Current
0.12%
Delta
-0.01%
Cash Generation Decreased
Previous
28.79%
Current
-39.61%
Delta
-68.39%
Growth Decreased
Previous
47.46%
Current
-6.61%
Delta
-54.07%
Inventory Pressure Increased
Previous
6.61%
Current
24.27%
Delta
17.66%
Margin Decreased
Previous
83.29%
Current
77.05%
Delta
-6.25%
Profitability Decreased
Previous
9.95%
Current
-8.77%
Delta
-18.72%
R And D Intensity Increased
Previous
26.40%
Current
27.65%
Delta
1.25%
Sbc Intensity Increased
Previous
4.78%
Current
6.85%
Delta
2.07%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · AKBA Fundamental State →Transitioned To · AKBA Fundamental State →Transitioned To · AKBA BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · AKBA CAPEX_INTENSITY_DECREASED →Transitioned To · AKBA CASH_GENERATION_DECREASED →Transitioned To · AKBA GROWTH_DECREASED →Transitioned To · AKBA INVENTORY_PRESSURE_INCREASED →Transitioned To · AKBA MARGIN_DECREASED →Transitioned To · AKBA PROFITABILITY_DECREASED →Transitioned To · AKBA R_AND_D_INTENSITY_INCREASED →Transitioned To · AKBA SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.